In a report released today, Devin Ryan from JMP Securities reiterated a Buy rating on Stifel Financial (SF – Research Report), with a price ...

POLAND — It is with great sadness that we announce the passing of Michael A. Mike Jr., 70, who passed away unexpectedly Saturday afternoon, Jan. 18, 2025. Michael was born Sept. 19, 1954 ...

Through his daughter Isabella’s toughest times, after her brain tumor was removed and she was undergoing another round of chemotherapy, Michael Strahan kept looking "to find the silver lining ...

In his review, my colleague Michael Phillips called it “a Hollywood love letter to Bob Dylan” but wished it “had as much nerve as it did craftsmanship.” It’s a fine movie, but I wish ...

Michael Andrew Malan was born March 7th, 1963, to Joann and Fred Malan, and passed away on Tuesday, January 21st, 2025. To know what he did for a living, starting with jewelry at Grasshopper Flats ...

Good day and welcome to the Stifel Financial fourth quarter financial results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr ...

Also, President Michael Greenberg sold 10,274 shares of Skechers U.S.A. stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $67.48, for a ...

NYSE AOS opened at $67.27 on Friday. A. O. Smith has a fifty-two week low of $65.53 and a fifty-two week high of $92.44. The stock’s 50-day moving average is $70.71 and its two-hundred day ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Michael McIntyre is due to return to TV screens with a new series of his BBC show, Michael McIntyre's Big Show, and he's given fans a glimpse of what to expect. The hit programme will be back on ...

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...